CorMedix Inc.
Moat Score — CorMedix Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | DefenCath's FDA approval as a first-in-class CRBSI-reduction therapy plus patents around its taurolidine/heparin formulation provide real regulatory and IP-based protection. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Outsourced, single-source contract manufacturing keeps costs lean but provides no structural cost advantage versus larger specialty pharma rivals. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the only approved therapy in its specific CRBSI-reduction niche, DefenCath commands real pricing power, though dialysis reimbursement policy (CMS/ESRD PPS) constrains it somewhat. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effects; adoption depends on clinical evidence and payer/formulary decisions, not user-driven value creation. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Existing supply agreements covering ~60% of the outpatient dialysis market and established hospital formulary placements create meaningful contracting and clinical-protocol switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The CRBSI-reduction niche is relatively small and specialized, but the broader hospital anti-infective market Melinta operates in is large and competitive, limiting an efficient-scale moat. |